• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本老年人血压控制和代谢综合征与心血管风险的关系:JATOS 研究。

Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study.

机构信息

Division of Hypertension and Nephrology, National Cerebral and Cardiovascular Center, Osaka, Japan.

出版信息

Am J Hypertens. 2011 Nov;24(11):1250-6. doi: 10.1038/ajh.2011.138. Epub 2011 Aug 4.

DOI:10.1038/ajh.2011.138
PMID:21814293
Abstract

BACKGROUND

The impact of the metabolic syndrome (MS) on cardiovascular events in elderly subjects has not been clarified. We hypothesized that the impact differs between patients with and without strictly controlled blood pressure (BP) and also between early elderly (<75 years) and late (≥75 years) elderly patients.

METHODS

Elderly hypertensive patients (65-85 years old) were randomly assigned to strict (target systolic BP <140 mm Hg) or mild (140-159 mm Hg) BP target, and were treated for 2 years with efonidipine-based regimen. MS was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria, except for the use of body mass index (BMI) ≥25 kg/m(2) instead of waist circumference. Primary endpoint was combined incidence of cardiovascular and renal events. Data were obtained from 2,865 patients.

RESULTS

The prevalence of MS was 31.4%. The incidence of primary endpoint in patients with and without MS was 4.0% and 3.1%, respectively. MS was a significant risk factor for cardiovascular events in patients <75 years old (adjusted hazard ratio (HR) 2.17, P = 0.01), but not in patients ≥75 years old (adjusted HR 0.98, P = 0.94). In patients with MS, the event rate was significantly lower with strict treatment than with mild treatment among patients aged <75 years (P = 0.0006) but not in those aged ≥75 years (P = 0.82).

CONCLUSIONS

MS was associated with cardiovascular risk in elderly hypertensive patients <75 years old, and strict BP control was beneficial for those with MS. However, MS and intensive control of BP may have little effect on cardiovascular events in elderly patients ≥75 years old.

摘要

背景

代谢综合征(MS)对老年患者心血管事件的影响尚未明确。我们假设,血压(BP)得到严格控制的患者与未得到严格控制的患者之间,以及年龄较轻(<75 岁)和较老(≥75 岁)的患者之间的影响存在差异。

方法

将 65-85 岁的老年高血压患者随机分配至严格(目标收缩压<140mmHg)或轻度(140-159mmHg)BP 目标,并接受依福地平为基础的方案治疗 2 年。MS 根据国家胆固醇教育计划成人治疗专家组 III 标准定义,除了使用体重指数(BMI)≥25kg/m2 代替腰围。主要终点是心血管和肾脏事件的综合发生率。数据来自 2865 例患者。

结果

MS 的患病率为 31.4%。MS 患者和无 MS 患者的主要终点发生率分别为 4.0%和 3.1%。MS 是年龄<75 岁患者心血管事件的显著危险因素(调整后的危险比(HR)为 2.17,P=0.01),但不是年龄≥75 岁患者的危险因素(调整后的 HR 为 0.98,P=0.94)。在 MS 患者中,与轻度治疗相比,年龄<75 岁的患者中严格治疗的事件发生率显著降低(P=0.0006),但在年龄≥75 岁的患者中则没有(P=0.82)。

结论

MS 与年龄<75 岁的老年高血压患者的心血管风险相关,严格的 BP 控制对 MS 患者有益。然而,MS 和强化 BP 控制可能对年龄≥75 岁的老年患者的心血管事件影响不大。

相似文献

1
Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study.日本老年人血压控制和代谢综合征与心血管风险的关系:JATOS 研究。
Am J Hypertens. 2011 Nov;24(11):1250-6. doi: 10.1038/ajh.2011.138. Epub 2011 Aug 4.
2
Comparison of strict- and mild-blood pressure control in elderly hypertensive patients: a per-protocol analysis of JATOS.老年高血压患者强化降压与温和降压的比较:JATOS 的方案内分析。
Hypertens Res. 2010 Nov;33(11):1124-8. doi: 10.1038/hr.2010.144. Epub 2010 Aug 5.
3
Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine.依福地平治疗老年高血压患者的肾功能对心血管事件的影响。
Hypertens Res. 2010 Nov;33(11):1211-20. doi: 10.1038/hr.2010.162. Epub 2010 Sep 16.
4
Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS).日本评估老年高血压患者最佳收缩压的试验(JATOS)的主要结果。
Hypertens Res. 2008 Dec;31(12):2115-27. doi: 10.1291/hypres.31.2115.
5
Is metabolic syndrome a risk factor for cardiovascular disease in late elderly?
Am J Hypertens. 2011 Nov;24(11):1193. doi: 10.1038/ajh.2011.161.
6
The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months.日本老年高血压患者最佳收缩压评估试验(JATOS):方案、患者特征及前12个月的血压情况
Hypertens Res. 2005 Jun;28(6):513-20. doi: 10.1291/hypres.28.513.
7
Efonidipine improves renal function and decreases proteinuria in elderly hypertensive patients in the JATOS study.在JATOS研究中,依福地平可改善老年高血压患者的肾功能并减少蛋白尿。
Hypertens Res. 2010 Nov;33(11):1112-3. doi: 10.1038/hr.2010.150. Epub 2010 Sep 2.
8
Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan's Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE).老年高血压患者降压治疗对心血管事件的影响:日本老年高血压降压效果研究(J-BRAVE)。
Clin Exp Hypertens. 2011;33(2):133-40. doi: 10.3109/10641963.2010.546467. Epub 2011 Jan 26.
9
Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension.依福地平可同时改善非糖尿病高血压患者的血压、内皮功能和代谢参数。
Diabetes Care. 2007 Jun;30(6):1605-7. doi: 10.2337/dc06-2267. Epub 2007 Mar 10.
10
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.马尼地平与氨氯地平治疗老年单纯收缩期高血压的降压疗效及安全性:MAISH研究
Clin Drug Investig. 2007;27(9):623-32. doi: 10.2165/00044011-200727090-00004.

引用本文的文献

1
Interplay between triglyceride-glucose index and cardiovascular events in hypertensive patients with controlled blood pressure (SBP<140 mmHg): insights from the SPRINT trial.血压控制良好(收缩压<140 mmHg)的高血压患者中甘油三酯-葡萄糖指数与心血管事件的相互作用:来自收缩压干预试验(SPRINT)的见解
Front Endocrinol (Lausanne). 2025 Jul 16;16:1508667. doi: 10.3389/fendo.2025.1508667. eCollection 2025.
2
Intensive Blood Pressure Strategy on Cardiovascular Diseases in Patients With Metabolic Syndrome: Post Hoc Analysis of a Clinical Trial.强化血压控制策略对代谢综合征患者心血管疾病的影响:一项临床试验的事后分析
J Am Heart Assoc. 2025 Mar 18;14(6):e036820. doi: 10.1161/JAHA.124.036820. Epub 2025 Mar 13.
3
Higher blood pressure targets for hypertension in older adults.
老年人高血压的更高血压目标
Cochrane Database Syst Rev. 2024 Dec 17;12(12):CD011575. doi: 10.1002/14651858.CD011575.pub3.
4
Blood pressure targets for hypertension in older adults.老年人高血压的血压目标
Cochrane Database Syst Rev. 2017 Aug 8;8(8):CD011575. doi: 10.1002/14651858.CD011575.pub2.
5
The Association between Sarcopenic Obesity and Depressive Symptoms in Older Japanese Adults.日本老年人群中肌肉减少性肥胖与抑郁症状之间的关联。
PLoS One. 2016 Sep 14;11(9):e0162898. doi: 10.1371/journal.pone.0162898. eCollection 2016.
6
Metabolic syndrome, sarcopenia and role of sex and age: cross-sectional analysis of Kashiwa cohort study.代谢综合征、肌肉减少症以及性别和年龄的作用:柏市队列研究的横断面分析
PLoS One. 2014 Nov 18;9(11):e112718. doi: 10.1371/journal.pone.0112718. eCollection 2014.
7
The relationship between metabolic syndrome and target organ damage in Ghanaian with stage-2 hypertension.加纳2期高血压患者代谢综合征与靶器官损害之间的关系。
Ghana Med J. 2013 Dec;47(4):189-96.
8
Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.奥美沙坦与雷米普利治疗老年高血压患者的比较:两项已发表的随机双盲研究数据综述
High Blood Press Cardiovasc Prev. 2014 Mar;21(1):1-19. doi: 10.1007/s40292-013-0037-9. Epub 2014 Jan 17.
9
Metabolic syndrome and functional ability in older age: the InCHIANTI study.代谢综合征与老年人群的功能能力:IN-CHIANTI 研究。
Clin Nutr. 2014 Aug;33(4):626-33. doi: 10.1016/j.clnu.2013.08.005. Epub 2013 Aug 23.
10
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.奥美沙坦酯-氨氯地平复方制剂与雷米普利治疗伴或不伴代谢综合征的老年轻中度原发性高血压患者的降压疗效和安全性:两项对照研究的事后 pooled 分析。
Drugs Aging. 2012 Dec;29(12):981-92. doi: 10.1007/s40266-012-0030-3.